A study conducted in India and published in the International Journal of Advanced Science and Engineering, showed that gingerol phytocomposite gingerol, an ginger extract can act as a promising drug to treat SARS CoV-2 virus, known as COVID-19.
Due to variability in amino acid sequences, no adjustable viral protein vaccines have been developed. Therefore, the develop treatments against coronavirus viral proteins with structures based on photochemical components.
This phytocompound designed from gingerol was identified and studied against viral receptors by using the molecular coupling technique.
“This study attempted to prove that Zingiber’s phytocompound 6-gingerol officinale
“6- Ginger has excellent drug parameters with zero violations of different rules and very good ADME pharmacokinetic properties”, study says.
The study also tests antiviral efficiency against COVID-19 by attacking different types of proteins.
“6-gingerol demonstrates antiviral efficiency against COV-2 SARS by showing the highest binding affinity and interaction with multiple COVID-19 targets incluyendo including viral proteases, RNA binding protein, Spike protein. The DFT study finally shows the reason behind the increased binding affinity between 6- gingerol and COVID-19 protein targets,” the report concludes.
Ginger is a planta native to Southeast Asia and belongs to family of Zingiberaceae. In India people traditionally this medicinal herb to strengthen their immune system.
This spice and traditional medicine have pharmacological activities, such as antibacterial, antioxidants, analgesics and antivirals
Ginger is also one of the best phyto-compound options in traditional medicine in Ayurvedic, traditional Asian systems for treating different diseases in ancient times.
in Costa Rica. 
